PARP Inhibitor Market By Drug (Lynparza, Niraparib, Rucaparib and Others), By Indication (Ovarian cancer, Breast cancer, Prostate cancer, Lung cancer and Others), By Distribution Channel (Hospital pharmacies, Online pharmacies and Others), and By Region - Trends, Analysis and Forecast till 2034

Report Code: PMI466821 | Publish Date: April 2024 | No. of Pages: 180

Global PARP Inhibitor Market Companies

  • AstraZeneca Plc.
  • Johnson & Johnson
  • GlaxoSmithKline plc.
  • Pfizer, Inc.
  • Jiangsu Hengrui Medicine Co., Ltd
  • Clovis Oncology Inc.
  • AbbVie Inc.
  • Bristol - Myers Squibb
  • Merck KGaA
  • Genentech, Inc.

Recent News:

  • In March 2024, Zydus Lifesciences on Wednesday said it has launched olaparib, a PARP inhibitor, under the brand name IBYRA in India, making advanced cancer treatment accessible to all.